{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:54:58Z","timestamp":1781636098318,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Swallowing development is a crucial outcome measure for evaluating the effectiveness of disease-modifying therapies (DMT) in children with spinal muscular atrophy (SMA). However, data on this aspect remain limited due to a lack of assessment tools. This study aimed to evaluate swallowing development in infants and toddlers with SMA, compare it with healthy controls (HC), and investigate the influence of initial symptom status at start of DMT and\n                      <jats:italic>SMN2<\/jats:italic>\n                      copy number.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      An observational study was conducted with infants and toddlers diagnosed with SMA at a single neuropediatric center and a HC group. Swallowing development was primarily assessed using the DySMA scale. Group differences and the impact of initial symptom status and\n                      <jats:italic>SMN2<\/jats:italic>\n                      copy number on swallowing were analyzed using linear mixed-effects models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included 127 infants and toddlers, 35 with SMA (0\u201336 months, 19 girls), who started DMT either presymptomatically (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200918) or symptomatically (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200917), with two (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200926) or three (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20099)\n                      <jats:italic>SMN2<\/jats:italic>\n                      copies, predominantly receiving Onasemnogene abeparvovec alone (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200926), and a healthy control group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200992, 0\u201323 months, 34 girls). Children with SMA displayed significantly different swallowing development trajectories (-0.06 DySMA points by months of life,\n                      <jats:italic>p<\/jats:italic>\n                      =.06; 95% CI -0.13 to 0.01) compared to HC (+\u20090.45 DySMA points by months of life,\n                      <jats:italic>p<\/jats:italic>\n                      &lt;.01, 95% CI 0.25 to 0.65). Notably, those treated presymptomatically demonstrated swallowing progress comparable to HC up to 15\u201317 months but experienced a decline thereafter (18\u201324 months; \u03b2\u2009=\u20098.22,\n                      <jats:italic>p<\/jats:italic>\n                      &lt;.001; 95% CI 4.20 to 12.26). The group with three\n                      <jats:italic>SMN2<\/jats:italic>\n                      copies exhibited a developmental pattern similar to HC up to the age of 24 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Higher\n                      <jats:italic>SMN2<\/jats:italic>\n                      copy number and presymptomatic DMT initiation were associated with similar early swallowing development compared to HC. Long-term studies stratifying swallowing development by\n                      <jats:italic>SMN2<\/jats:italic>\n                      copy number are warranted.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04227-3","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T08:55:55Z","timestamp":1771232155000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Swallowing development in infants and toddlers with spinal muscular atrophy following therapy compared to healthy controls: the prospective controlled DySMA trial"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4979-4716","authenticated-orcid":false,"given":"Jana","family":"Zang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Dumitrascu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Glinzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deike","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Denecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Pflug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almut C.","family":"Niessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Steffens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessika","family":"Johannsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"4227_CR1","doi-asserted-by":"crossref","unstructured":"Mercuri E et al. Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment. Eur J Neurol. 2022.","DOI":"10.1111\/ene.15499"},{"issue":"1","key":"4227_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13023-019-0998-4","volume":"14","author":"A Pechmann","year":"2019","unstructured":"Pechmann A, et al. SMArtCARE - A platform to collect real-life outcome data of patients with spinal muscular atrophy. Orphanet J Rare Dis. 2019;14(1):18.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"4227_CR3","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1136\/jmg.2010.079004","volume":"47","author":"S Bernal","year":"2010","unstructured":"Bernal S, et al. The c.859G\u2009>\u2009C variant in the SMN2 gene is associated with types II and III SMA and originates from a common ancestor. J Med Genet. 2010;47(9):640\u20132.","journal-title":"J Med Genet"},{"issue":"3","key":"4227_CR4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00439-019-01983-0","volume":"138","author":"C Ruhno","year":"2019","unstructured":"Ruhno C, et al. Complete sequencing of the SMN2 gene in SMA patients detects SMN gene deletion junctions and variants in SMN2 that modify the SMA phenotype. Hum Genet. 2019;138(3):241\u201356.","journal-title":"Hum Genet"},{"issue":"1","key":"4227_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis. 2017;12(1):124.","journal-title":"Orphanet J Rare Dis"},{"key":"4227_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1750-1172-6-71","volume":"6","author":"A D\u2019Amico","year":"2011","unstructured":"D\u2019Amico A, et al. Spinal muscular atrophy. Orphanet J Rare Dis. 2011;6:71.","journal-title":"Orphanet J Rare Dis"},{"issue":"9630","key":"4227_CR7","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","volume":"371","author":"MR Lunn","year":"2008","unstructured":"Lunn MR, Wang CH. Spinal muscular atrophy. Lancet. 2008;371(9630):2120\u201333.","journal-title":"Lancet"},{"issue":"5","key":"4227_CR8","doi-asserted-by":"publisher","first-page":"889","DOI":"10.3233\/JND-230248","volume":"11","author":"Y Marti","year":"2024","unstructured":"Marti Y, et al. A systematic literature review of the natural history of Respiratory, Swallowing, Feeding, and speech functions in spinal muscular atrophy (SMA). J Neuromuscul Dis. 2024;11(5):889\u2013904.","journal-title":"J Neuromuscul Dis"},{"issue":"9","key":"4227_CR9","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","volume":"83","author":"RS Finkel","year":"2014","unstructured":"Finkel RS, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83(9):810\u20137.","journal-title":"Neurology"},{"issue":"3","key":"4227_CR10","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1044\/2021_AJSLP-20-00217","volume":"30","author":"KE McGrattan","year":"2021","unstructured":"McGrattan KE, et al. Dysphagia phenotypes in spinal muscular atrophy: the Past, Present, and promise for the future. Am J Speech Lang Pathol. 2021;30(3):1008\u201322.","journal-title":"Am J Speech Lang Pathol"},{"issue":"2","key":"4227_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S1090-3798(99)80012-9","volume":"3","author":"V Dubowitz","year":"1999","unstructured":"Dubowitz V. Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype. Eur J Pediatr Neurology: EJPN: Official J Eur Pediatr Neurol Soc. 1999;3(2):49\u201351.","journal-title":"Eur J Pediatr Neurology: EJPN: Official J Eur Pediatr Neurol Soc"},{"issue":"3","key":"4227_CR12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3233\/JND-190465","volume":"7","author":"AMB van der Heul","year":"2020","unstructured":"van der Heul AMB, et al. Feeding and swallowing problems in infants with spinal muscular atrophy type 1: an observational study. J Neuromuscul Dis. 2020;7(3):323\u201330.","journal-title":"J Neuromuscul Dis"},{"key":"4227_CR13","doi-asserted-by":"publisher","first-page":"109818","DOI":"10.1016\/j.ijporl.2019.109818","volume":"130","author":"YA Choi","year":"2020","unstructured":"Choi YA, et al. Trajectory of change in the swallowing status in spinal muscular atrophy type I. Int J Pediatr Otorhinolaryngol. 2020;130:109818.","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"21","key":"4227_CR14","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1212\/WNL.0b013e3181c34aa6","volume":"73","author":"L Van den Engel-Hoek","year":"2009","unstructured":"Van den Engel-Hoek L, et al. Dysphagia in spinal muscular atrophy type II: more than a bulbar problem? Neurology. 2009;73(21):1787\u201391.","journal-title":"Neurology"},{"issue":"5","key":"4227_CR15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.nmd.2008.02.008","volume":"18","author":"S Messina","year":"2008","unstructured":"Messina S, et al. Feeding problems and malnutrition in spinal muscular atrophy type II. Neuromuscul Disord. 2008;18(5):389\u201393.","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"4227_CR16","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1002\/ppul.26919","volume":"59","author":"C Leon-Astudillo","year":"2024","unstructured":"Leon-Astudillo C, et al. Longitudinal changes of swallowing safety and efficiency in infants with spinal muscular atrophy who received disease modifying therapies. Pediatr Pulmonol. 2024;59(5):1364\u201371.","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"4227_CR17","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s00405-022-07685-0","volume":"280","author":"J Zang","year":"2023","unstructured":"Zang J, et al. Flexible endoscopic evaluation of swallowing in children with type 1 spinal muscular atrophy. Eur Arch Otorhinolaryngol. 2023;280(3):1329\u201338.","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"5","key":"4227_CR18","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/mus.28224","volume":"70","author":"K O\u2019Brien","year":"2024","unstructured":"O\u2019Brien K, et al. Nutrition outcomes of disease modifying therapies in spinal muscular atrophy: A systematic review. Muscle Nerve. 2024;70(5):890\u2013902.","journal-title":"Muscle Nerve"},{"issue":"2","key":"4227_CR19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.27853","volume":"68","author":"TO Crawford","year":"2023","unstructured":"Crawford TO, et al. Continued benefit of Nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study. Muscle Nerve. 2023;68(2):157\u201370.","journal-title":"Muscle Nerve"},{"issue":"8","key":"4227_CR20","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.nmd.2023.06.005","volume":"33","author":"RD Shell","year":"2023","unstructured":"Shell RD, et al. Onasemnogene abeparvovec preserves bulbar function in infants with presymptomatic spinal muscular atrophy: a post-hoc analysis of the SPR1NT trial. Neuromuscul Disord. 2023;33(8):670\u20136.","journal-title":"Neuromuscul Disord"},{"key":"4227_CR21","doi-asserted-by":"publisher","first-page":"101092","DOI":"10.1016\/j.lanepe.2024.101092","volume":"47","author":"C Weiss","year":"2024","unstructured":"Weiss C, et al. Efficacy and safety of gene therapy with onasemnogene abeparvovec in children with spinal muscular atrophy in the D-A-CH-region: a population-based observational study. Lancet Reg Health Eur. 2024;47:101092.","journal-title":"Lancet Reg Health Eur"},{"issue":"4","key":"4227_CR22","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3233\/JND-221672","volume":"10","author":"S Dunaway Young","year":"2023","unstructured":"Dunaway Young S, et al. Development of an international SMA bulbar assessment for Inter-professional administration. J Neuromuscul Dis. 2023;10(4):639\u201352.","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"4227_CR23","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3233\/JND-230177","volume":"11","author":"J Zang","year":"2024","unstructured":"Zang J, et al. DySMA\u2013an instrument to monitor swallowing function in children with spinal muscular atrophy ages 0 to 24 months: Development, Consensus, and pilot testing. J Neuromuscul Dis. 2024;11(2):473\u201383.","journal-title":"J Neuromuscul Dis"},{"issue":"7624","key":"4227_CR24","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806\u20138.","journal-title":"BMJ"},{"key":"4227_CR25","doi-asserted-by":"publisher","first-page":"112345","DOI":"10.1016\/j.ijporl.2025.112345","volume":"193","author":"C Dumitrascu","year":"2025","unstructured":"Dumitrascu C, et al. Feeding development in healthy infants: A comparative framework for children with spinal muscular Atrophy\u2013The dysmanorm study. Int J Pediatr Otorhinolaryngol. 2025;193:112345.","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"9","key":"4227_CR26","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/dmcn.15542","volume":"65","author":"E Hanks","year":"2023","unstructured":"Hanks E, et al. Consensus on level descriptors for a functional children\u2019s eating and drinking activity scale. Dev Med Child Neurol. 2023;65(9):1199\u2013205.","journal-title":"Dev Med Child Neurol"},{"issue":"3","key":"4227_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","volume":"20","author":"AM Glanzman","year":"2010","unstructured":"Glanzman AM, et al. The children\u2019s hospital of Philadelphia infant test of neuromuscular disorders (CHOP INTEND): test development and reliability. Neuromuscul Disord. 2010;20(3):155\u201361.","journal-title":"Neuromuscul Disord"},{"key":"4227_CR28","unstructured":"Core Team R. R., R: A language and environment for statistical computing [Internet]. Vienna, Austria: R foundation for statistical computing; 2015: pp. 171\u2013203."},{"issue":"1","key":"4227_CR29","first-page":"p2","volume":"12","author":"D Bates","year":"2015","unstructured":"Bates D, et al. Package \u2018lme4\u2019. Convergence. 2015;12(1):p2.","journal-title":"Convergence"},{"issue":"1","key":"4227_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12874-019-0876-8","volume":"20","author":"MJ Monsalves","year":"2020","unstructured":"Monsalves MJ, et al. Logical explanations & visualizations of estimates in linear mixed models): recommendations for reporting multilevel data and analyses. BMC Med Res Methodol. 2020;20(1):3.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"4227_CR31","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13023-024-03524-z","volume":"20","author":"J Zang","year":"2025","unstructured":"Zang J, et al. Maximal mouth opening in infants and toddlers with spinal muscular atrophy: a prospective controlled study. Orphanet J Rare Dis. 2025;20(1):24.","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"4227_CR32","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1007\/s00431-022-04470-3","volume":"181","author":"M Pane","year":"2022","unstructured":"Pane M, et al. Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening. Eur J Pediatrics. 2022;181(7):2821\u20139.","journal-title":"Eur J Pediatrics"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04227-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04227-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04227-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:18:42Z","timestamp":1781633922000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04227-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4227"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04227-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The local ethics committee \u201cHamburger \u00c4rztekammer\u201d has approved the study (2022-100827_2-BO-ff). All parents have given written informed consent to participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All parents have given written informed consent to publication of the anonymous data. Consent for publication has been granted for all images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We used the large language model UHHGPT, based on GPT-4.1 Nano, a special version used at the University of Hamburg, to assist with verifying the grammar and spelling of some parts of the manuscript. The specific prompt provided was: \" please check grammar and spelling in the following sentence and suggest improvements if necessary.\u201d The model was used exclusively for language editing purposes.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"AI disclosure"}},{"value":"The study data are reported in this manuscript and its supplement. Further data are available from the corresponding author on reasonable request from the moment of publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing"}},{"value":"No author received financial support for the present manuscript. JZ received funding from \u201cInitative f\u00fcr die Spinale Muskelatrophie\/Deutsche Gesellschaft f\u00fcr Muskelkranke\u201d and from \u201eHamburg macht Kinder gesund e.V.\u201c. JG receives doctoral funding from the University of Hamburg as part of the State Graduate Funding Program of the city of Hamburg. DW received compensation for advisory boards and funding for travel or speaker honoraria from Biogen and Roche. CP received speaker honoraria and funding for travel from Infectopharm, Xion and Bial. JJ received compensation for advisory boards and funding for travel or speaker honoraria from Avexis\/Novartis, Biogen, IFT, Roche, Santhera Therapeutics, PTC, Pfizer, and Sarepta Therapeutics. CD, AN, and PS and JD indicated no potential conflicts of interest to disclose.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"105"}}